Skip to main content

Table 1 Attenuation of key pathways in systemic sclerosis: agents for evaluation

From: Therapeutic targets in systemic sclerosis

Candidate therapy

Target pathway

Bosentan

ETA/ETB pathway

Imatinib

PDGF receptor signalling

signalling Infliximab

TNF-α

Adalimumab

TNF-α

Etanercept

TNF-α

CAT-192

TGF-β1

GC-1008

TGF-β1, TGF-β2, TGF-β3

FG-3019

CTGF ligand

Alefacept

LFA3/CD2

Basiliximab

IL-2Rα

MLM-1202

CCR2

Efalizumab

LFA/ICAM-1

  1. CCR, CC chemokine receptor; ETA/B, endothelin receptor subtype A/B; CTGF, connective tissue growth factor; ICAM, intercellular adhesion molecule; IL-2Rα, interleukin-2 receptor α; LFA, lymphocyte function associated; PDGF, platelet-derived growth factor; TGF, transforming growth factor; TNF, tumour necrosis factor.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us